
How Participation in a Securities Fraud Class Action Works
Guide to securities fraud class actions and how investors participate.

Kyndryl Holdings (KD) Securities Class Action: Internal Controls, Cash Flow Reporting, and a 55% Stock Collapse
Learn about securities lawsuits tied to your portfolio and recover money!
Kyndryl Holdings, Inc. did not implode in a single moment. It unraveled in increments: quarterly filings, repeated assurances, and internal control language that, investors allege, masked deeper structural failures. On February 11, 2026, a federal securities class action was filed in the U.S. District Court for the Eastern District of New York accusing Kyndryl and senior executives of issuing materially false and misleading statements about internal controls and cash-flow reporting.
The reckoning arrived on February 9, 2026, when Kyndryl disclosed it could not timely file a required Form 10-Q and revealed an SEC investigation into its financial reporting. The market reaction was swift and unforgiving. Shares fell 55% in a single session. For investors, the case raises familiar but unresolved questions about disclosure controls, “tone at the top,” and how long accounting weaknesses can hide in plain sight.
“Most KD shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Kyndryl is a technology services company focused on infrastructure services, operating at scale for enterprise clients. The company became a standalone public entity following its spin-off from IBM, inheriting complex systems, compressed transition timelines, and legacy operational dependencies.
According to the complaint, Kyndryl’s post-spin environment required a rapid migration of internal operating systems to a new enterprise resource planning platform. Management repeatedly attributed internal-control weaknesses to information technology general controls tied to that migration. Investors allege the company downplayed broader internal control issues by characterizing the problem as limited to IT general controls tied to the migration.
Throughout the Class Period, Kyndryl executives repeatedly addressed the company’s internal control environment in periodic filings and investor disclosures. Management acknowledged certain deficiencies in information technology general controls but assured investors that those issues had not resulted in misstatements of the company’s consolidated financial statements.
According to the complaint, Kyndryl continued to frame the issue as a contained control matter tied largely to systems migration and implementation challenges. In multiple quarterly filings, the company stated that although certain disclosure controls and procedures were not effective, the identified deficiencies had not resulted in errors in previously issued financial statements.
The tone shifted in 2025. In its annual report for fiscal year 2025, Kyndryl reported that internal control over financial reporting and disclosure controls were effective as of March 31, 2025, signaling to investors that earlier control issues had been resolved. Similar conclusions appeared in subsequent quarterly filings during fiscal 2026.
Plaintiffs allege that those assurances painted an incomplete picture of the company’s internal control environment. According to the complaint, the underlying problems extended beyond limited IT control deficiencies and included weaknesses tied to financial reporting processes and cash management practices.
Rather than a contained technical issue, investors now allege they were facing a broader internal control breakdown, one that would later force the company to reassess prior conclusions about the effectiveness of its controls and the reliability of previously issued financial statements.
The alleged misconduct begins on August 7, 2024, when Kyndryl filed its Form 10-Q for the first quarter of fiscal year 2025. In that filing, the company acknowledged a material weakness in certain information technology general controls and reported that its disclosure controls and procedures were not effective, while also stating that the identified deficiencies had not resulted in a misstatement of the company’s consolidated financial statements.
Kyndryl repeated similar language in subsequent quarterly filings, including its Form 10-Q filed November 7, 2024 (2Q FY2025) and Form 10-Q filed February 6, 2025 (3Q FY2025).
In its Form 10-K filed May 30, 2025 for fiscal year 2025, however, management concluded that internal control over financial reporting and disclosure controls were effective as of March 31, 2025. Kyndryl maintained that position in later filings, including the Form 10-Q filed August 5, 2025 (1Q FY2026) and Form 10-Q filed November 5, 2025 (2Q FY2026).
According to the complaint, those assurances allegedly failed to reflect the company’s true control environment and the extent of weaknesses affecting financial reporting.
The situation came to a head on February 9, 2026, when Kyndryl filed a Notification of Late Filing (Form 12b-5) with the SEC stating it could not timely file its Form 10-Q for the quarter ended December 31, 2025. The company also disclosed that the SEC’s Division of Enforcement had made voluntary document requests related to cash management practices, related disclosures, including drivers of its adjusted free cash flow metric and the effectiveness of internal control over financial reporting.
Through its Audit Committee, Kyndryl announced an internal review of those matters and said it expected to report material weaknesses in internal control over financial reporting affecting multiple periods, including fiscal year 2025 and the first two quarters of fiscal 2026. The company further stated that its earlier conclusion that internal controls were effective as of March 31, 2025 should no longer be relied upon.
Investors learned of these developments before the market opened on February 9, 2026.
According to the complaint, Kyndryl’s stock fell $12.90 per share, or approximately 55%, to close at $10.59 on the New York Stock Exchange that day.
Plaintiffs allege that the decline followed the company’s disclosures regarding its late filing, the SEC’s document requests concerning cash management practices and related disclosures, and its expectation that previously reported internal control conclusions would need to be revised.
From an investor-impact perspective, the magnitude of the drop matters less than its cause. Sudden control-related disclosures, especially those involving SEC investigations and withdrawn reliance on audited controls, tend to reprice risk instantly. This case fits that pattern.
The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Defendants include Kyndryl and senior executives Martin J. Schroeter (CEO), David B. Wyshner (former CFO), and Vineet Khurana (former Global Controller).
The complaint points to SOX certifications and signatory roles in certain SEC filings, and alleges that the challenged statements were false or misleading when made. The case is in its early stages, with damages, class certification, and motion-to-dismiss proceedings yet to unfold.
Retail investor sentiment toward Kyndryl shifted quickly following the company’s February 2026 disclosures.
Discussions across retail-investor platforms such as Reddit and Stocktwits reflected a surge in attention after Kyndryl revealed a delayed quarterly filing, an internal accounting review, and voluntary document requests from the U.S. Securities and Exchange Commission related to cash-management practices and internal controls. Conversation on those platforms often centered on whether the disclosures pointed to a temporary reporting disruption or a deeper breakdown in the company’s control environment.
Financial media coverage noted that the combination of an SEC inquiry, anticipated material weaknesses in internal control over financial reporting, and abrupt executive departures intensified investor scrutiny of the company’s earlier assurances about its reporting processes.
Against that backdrop, the complaint alleges that investors reassessed Kyndryl’s disclosures once the February 2026 developments became public.
Analyst reaction following Kyndryl’s February 2026 disclosures focused on uncertainty surrounding the company’s financial reporting and oversight.
Financial press coverage noted that the delayed filing, accounting review, and senior executive departures raised questions about the reliability of previously reported financial metrics and the company’s internal control framework.
Market reporting also highlighted that the departures of Kyndryl’s chief financial officer and other senior finance leaders coincided with the company’s announcement of the accounting review and delayed filing, developments that intensified scrutiny of the company’s governance and reporting processes.
Coverage of the disclosures noted that the company’s shares fell roughly 55% following the announcement of the accounting review and leadership departures, underscoring investor concern about the implications for financial reporting reliability and internal controls.
More broadly, financial media coverage commentary surrounding the event observed that accounting reviews and disclosures of internal control weaknesses can create uncertainty for investors until companies clarify the scope of the issues and outline remediation efforts.
Kyndryl’s SEC filings during the class period included repeated discussions of internal-control remediation tied to IT system migrations. Plaintiffs allege that these disclosures omitted or minimized broader weaknesses affecting financial reporting reliability.
The February 2026 Form 12b-5 and accompanying disclosures marked a turning point explicitly acknowledging material weaknesses across multiple reporting periods and disavowing reliance on prior internal-control assessments. For investors, this sequence underscores the importance of tracking not just risk-factor language, but how consistently management updates or fails to update those risks over time.
The Kyndryl case is not about a missed quarter. The lawsuit centers on a familiar question in securities litigation: whether the market was given the full picture about a company’s internal controls.
Shareholders allege that Kyndryl repeatedly characterized control issues as limited and later reported that its internal control framework was effective. Investors now contend those assurances understated deeper problems that later surfaced through a delayed SEC filing, an accounting review, and scrutiny of the company’s reporting practices.
For investors in complex, post-spin companies, the lesson is familiar but costly: remediation narratives deserve as much scrutiny as growth stories.
How to Join the Kyndryl Holdings, Inc. (KD) Class Action
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Guide to securities fraud class actions and how investors participate.

Inovio Pharmaceuticals (INO) Securities Class Action: FDA Setback, Manufacturing Deficiencies, and the Cost of Delayed Truth
![Picard Medical, Inc. (PMI) Securities Class Action Update [February 10, 2026]](https://media.suewallst.com/cms-dev/PMI_Blog_Cover_74654de563.jpeg)
Picard Medical faces a securities class action after its low-float IPO allegedly enabled a pump-and-dump scheme that led to investor losses.